Skip Navigation



JAC Advance Access published online on December 22, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki457
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/2/221    most recent
dki457v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Alvarado-Esquivel, C.
Right arrow Articles by Sablon, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alvarado-Esquivel, C.
Right arrow Articles by Sablon, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original article

Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico

Cosme Alvarado-Esquivel 1 *, Manuela de la Ascensión Carrera-Gracia 1, Carlos Jesús Conde-González 2, Luis Juárez-Figueroa 2, Lilia Ruiz-Maya 3, Sergio Aguilar-Benavides 3, Alejandro Torres-Valenzuela 1, and Erwin Sablon 4

1 Faculty of Medicine, Universidad Juárez del Estado de Durango, Durango, Dgo, Mexico
2 National Institute of Public Health, Cuernavaca, Morelos, Mexico
3 Regional Laboratory of Epidemiologic Reference, Guadalajara, Jal, Mexico
4 Innogenetics N.V., Ghent, Belgium

* To whom correspondence should be addressed.
Cosme Alvarado-Esquivel, E-mail: alvaradocosme{at}yahoo.com


  Abstract

Background: Drug resistance of hepatitis B virus (HBV) is an increasing clinical problem. Resistance to lamivudine in HBV isolates in Mexico has been poorly explored.

Objectives: To characterize the mutation patterns associated with genotypic resistance to lamivudine and their prevalence among HBV isolates in Mexico.

Material and methods: Thirty-nine Mexican HBV isolates were analysed by PCR and line probe assay for detection of genetic variants in the polymerase open reading frame domains B and C (INNO-LiPA HBV DR; INNOGENETICS N. V., Ghent, Belgium). This assay detects wild-type and mutations at codons 180, 204 and 207 of the HBV polymerase gene, and at codon positions 171, 172, 195, 196, 198 and 199 of the HBV surface antigen (HBsAg). HBV isolates were obtained from HBsAg-positive serum samples of 15 chronic hepatitis patients, two haemodialysis patients with chronic HBV carriage, 20 men found positive for HBsAg when seeking HIV testing and two AIDS patients with chronic HBV infection. None of the participants had received antiviral therapy.

Results: Overall, HBV wild-type was found in 37 (94.9%) out of the 39 isolates studied. Two (5.1%) out of the 39 isolates showed mixed wild-type and mutant populations. These mutations occurred in isolates from one hepatitis patient and one haemodialysis patient. The isolate from the hepatitis patient showed a double mutation at codon positions 180 (L180M) and 204 (M204V), thus a 2.6% prevalence of genotypic resistance to lamivudine was found. The isolate from the haemodialysis patient showed a single mutation at codon position 180 (L180M). The two HBV mutant isolates were further analysed for genotype and both isolates were genotype H.

Conclusions: HBV genotypic resistance to lamivudine exists in Mexican isolates. The results highlight the importance of testing for HBV resistance before treatment and have implications for a more rational use of drugs.

Keywords: drug resistance; mutations; viral infections.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.